SYNLAB UK & Ireland:

Modern Slavery & Human Trafficking Statement 2022

Published: 1st August 2022 - All information correct at time of publication.

Introduction

This is SYNLAB UK and Ireland’s Modern Slavery and Human Trafficking Statement under Section 54 of the UK Modern Slavery Act 2015 for the financial year 2021. Modern slavery is a broad term that encompasses slavery, servitude, forced and compulsory labour and human trafficking. SYNLAB UK&I is part of SYNLAB Group which is committed to the UK Government’s objectives of eradicating modern slavery and human trafficking. The SYNLAB Group is committed to ensuring that the supply chains of its subsidiaries and their business activities are free from ethical and labour standards abuse. This statement summarises the measures that the SYNLAB Group has taken to assess and address the risk of modern slavery in its business and supply chains.

Our Organisational Structure, Business Model & Supply Chain

SYNLAB AG is the ultimate parent company of all the subsidiaries that belong to the SYNLAB Group of companies (SYNLAB) during 2021. SYNLAB AG provides head office support activities to its subsidiaries by way of providing guidelines, advice and assistance, including to SYNLAB UK&I. SYNLAB Bondco PLC is ultimately owned by SYNLAB AG and a non-operational debt issuing vehicle, providing financing to the SYNLAB Group. Our UK operating business activities are carried out by Labco UK Group Limited and its subsidiaries.

We are an international diagnostic service provider. We provide analytical, diagnostical and pathological ser- vices in the field of human and veterinary medicine diagnostic. SYNLAB Group offer services in 36 countries across four continents (Europe, Latin America, Africa and Middle East/Asia), having more than 24,000 employees including 2,700 employees across the UK and Ireland.

In providing our services, we rely on the supply of technical equipment provided by suppliers of analytical machinery and technology for laboratory analyses/diagnostic testing, as well as reagents and chemicals utilised in such testing. Goods and services are provided by professional services companies, subcontractors including couriers and sub-processors of test samples. In addition, we rely on external professional services providers in relation to our head office support, including financing related activities as well as its corporate and financial housekeeping.

Our Policies

We have adopted a Code of Conduct, which was reviewed 2021, setting out our commitment to act ethically and with integrity in all our business relationships. The updated Code of Conduct is currently being re-published within the UK and Ireland, along with new global ‘Speak Up’ reporting arrangements and updated Anti-Bribery, Anti-Corruption and Sanctions Guidelines. In addition, in the UK, we have adopted a dedicated policy on anti-slavery and human trafficking. All our employees must comply with all relevant laws and regulations (including those on modern slavery and human trafficking) and they must respect the personal dignity, rights, and diversity of everyone within and outside SYNLAB.

In 2021 SYNLAB Group developed a Supplier Code of Conduct as part of its plans for Responsible Supply Chain management, which will be implemented in 2022.

Training

To ensure a high level of understanding of the risks of modern slavery and human trafficking in our supply chains and our business, all starting and current employees in the UK have to complete a training module annually on modern slavery and human trafficking.

Due Diligence & Risk Assessment

We acknowledge that slavery and human trafficking exist in many jurisdictions in which we operate, and/or from which we procure goods or services. Our overall objective is to establish and maintain relationships with our suppliers that will minimise the risk that slavery or human trafficking could occur within our supply chains.

Our due diligence approach is based on inclusion of our relevant functional teams, such as legal, compliance, M&A, and procurement. We are continuing to invest in tackling modern slavery by implementing various instruments, including the introduction of MSA provisions in our supplier contracts and the circulation of supplier assessment questionnaires.

To mitigate against the risk of modern slavery and human trafficking in our supply chain, risk assessment and due diligence will continue to focus on our first-tier supplier relationships. It is understood that we need to refine our risk assessment in accordance of our findings. We are taking steps to establish frameworks in which all elements of our supply chain are expected to observe applicable laws and operate in accordance with our Code of Conduct.

We are taking steps to improve our systems and procedures to detect potential modern slavery and human trafficking risks arising around particular products and geographical areas.

SYNLAB AG has a dedicated Compliance Committee, which consists of the Group Chief Executive Officer and Group Chief Financial Officer, chaired by the Group Chief Compliance Officer. The Compliance Committee is supported by Regional Compliance Officers, which includes the Head of Legal and Compliance for the UK and Ireland.

Effective Actions Taken

We use the following key performance indicators to measure how effective we have been to ensure that slavery and human trafficking is not taking place in any part of our business or supply chain:

  • Anti-slavery and human trafficking clauses: We included an anti-slavery and human trafficking clause in our procurement templates. In addition, we are amending existing procurement contracts of our top global first tier supplier to confirm MSA compliance within our supply chain.
  • Training of our employees: We carried out modern slavery and human trafficking training for the vast majority of our employees.
  • CEO Message: Our Group CEO emphasised our social responsibility and ethical principles during regular CEO ‘check-in’ meetings.
  • ESG Initiative: We continued to embed an environmental, social and governance (ESG) initiative both in the UK and across all SYNLAB’s operations globally, aiming to reflect on the most significant ESG risks and opportunities from both SYNLAB and our stakeholders’ perspective. Modern slavery and human trafficking was part of our ESG Report published for 2021.
Looking Ahead

We understand that combating modern slavery and human trafficking is an ongoing imperative. In 2022, we will continue to invest in doing so. Our actions will comprise:

  • Policies: We will implement our Supplier Code of Conduct and re-publish an updated Code of Conduct for all SYNLAB’s workers.
  • Training for our Members: We will continue to raise awareness on modern slavery and human trafficking among our employees.
  • Supplier Questionnaire: We will continue to issue our supplier questionnaire to our suppliers, continuing to ensure that our supply chain complies with our ethical standards set out in our Code of Conduct.

Tom Evans

Director, SYNLAB Limited

For our 2021 Modern Slavery and Human Trafficking Statement please click here.

Latest SYNLAB UK & Ireland News
SYNLAB UK&I appoints new Synnovis CEO

SYNLAB UK & Ireland is delighted to announce the appointment of Tom Evans as Chief Executive Officer of Synnovis, its NHS partnership in South East…

Read More (about 'SYNLAB UK&I appoints new Synnovis CEO')
SYNLAB UK & Ireland partners with iFAST Diagnostics

We are proud to announce the expansion of our partnership with iFAST Diagnostics as its first commercial laboratory partner in the UK. Following validation earlier…

Read More (about 'SYNLAB UK & Ireland partners with iFAST Diagnostics')
SYNLAB UK & Ireland announces new Chief Medical Officer

SYNLAB UK & Ireland is delighted to announce the appointment of Dr John Burke as Chief Medical Officer. This appointment is pivotal to the advancement…

Read More (about 'SYNLAB UK & Ireland announces new Chief Medical Officer')
iFAST Diagnostics

We are proud to be partnering with iFAST Diagnostics to evaluate their new antimicrobial susceptibility testing (AST) system. The low-cost, high-throughput, bench top device can…

Read More (about 'iFAST Diagnostics')
Synnovis Logo
Synnovis completes forensic review following 2024 cyberattack — notifications under way

Synnovis, a pathology partnership between Guy’s and St Thomas’ NHS Foundation Trust, King’s College Hospitals NHS Trust and SYNLAB, has completed the forensic investigation of…

Read More (about 'Synnovis completes forensic review following 2024 cyberattack — notifications under way')
A single pathology service for mid and south Essex is confirmed from October 2026

Mid and South Essex NHS Foundation Trust has signed a 15-year contract with SYNLAB, one of UK’s leading laboratory diagnostics providers, for the delivery of…

Read More (about 'A single pathology service for mid and south Essex is confirmed from October 2026')
The Christie NHS Foundation Trust & SYNLAB announce new 15+ year contract

The Christie NHS Foundation Trust has signed a 15+ year contract with SYNLAB, the leading provider of medical diagnostic services and specialty testing in Europe,…

Read More (about 'The Christie NHS Foundation Trust & SYNLAB announce new 15+ year contract')
SYNLAB Chosen as Preferred Pathology Services Supplier for Mid and South Essex

Patients across mid and south Essex are set to benefit from a single provider of pathology services, following an intensive and competitive procurement process. SYNLAB,…

Read More (about 'SYNLAB Chosen as Preferred Pathology Services Supplier for Mid and South Essex')
SYNLAB Values Wheel
SYNLAB sets its Sights on Becoming the UK’s Leading Laboratory Diagnostics Organisation

Science for Life, Health and Wellbeing SYNLAB, the medical diagnostics provider, has set out its ambition to become the UK’s leading  laboratory diagnostics organisation by…

Read More (about 'SYNLAB sets its Sights on Becoming the UK’s Leading Laboratory Diagnostics Organisation')
Landmark Day for Pathology Partnership with Launch of Synnovis Brand

A pathology partnership performing 32 million tests a year has been relaunched as ‘Synnovis’ – officially heralding the start of a new era for clinicians…

Read More (about 'Landmark Day for Pathology Partnership with Launch of Synnovis Brand')
Pathology laboratory becomes the first in the UK to support remote plate reading  

A pathology laboratory is leading the way in speeding up access to patient care and treatment after becoming the first in the UK to enable…

Read More (about 'Pathology laboratory becomes the first in the UK to support remote plate reading  ')
SYNLAB ESG Roadmap and Framework

Introduction SYNLAB UK&I is thrilled to publish its UK&I ESG Framework and Roadmap, which outlines out how we will achieve our ESG Goals. In it…

Read More (about 'SYNLAB ESG Roadmap and Framework')